Literature DB >> 28857078

Cell signalling: Even kinase-inactive BRAF is oncogenic.

David Killock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28857078     DOI： 10.1038/nrclinonc.2017.140

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

Authors:  Zhan Yao; Rona Yaeger; Vanessa S Rodrik-Outmezguine; Anthony Tao; Neilawattie M Torres; Matthew T Chang; Matthias Drosten; Huiyong Zhao; Fabiola Cecchi; Todd Hembrough; Judith Michels; Hervé Baumert; Linde Miles; Naomi M Campbell; Elisa de Stanchina; David B Solit; Mariano Barbacid; Barry S Taylor; Neal Rosen
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962

2.  A Braf kinase-inactive mutant induces lung adenocarcinoma.

Authors:  Patricia Nieto; Chiara Ambrogio; Laura Esteban-Burgos; Gonzalo Gómez-López; María Teresa Blasco; Zhan Yao; Richard Marais; Neal Rosen; Roberto Chiarle; David G Pisano; Mariano Barbacid; David Santamaría
Journal:  Nature       Date:  2017-08-02       Impact factor: 49.962
  2 in total
  1 in total

1.  BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale.

Authors:  Jillian Wilhelmina Paulina Bracht; Niki Karachaliou; Trever Bivona; Richard B Lanman; Iris Faull; Rebecca J Nagy; Ana Drozdowskyj; Jordi Berenguer; Manuel Fernandez-Bruno; Miguel Angel Molina-Vila; Rafael Rosell
Journal:  Cancers (Basel)       Date:  2019-09-17       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.